Ambys Medicines, backed by Third Rock Ventures and a partner to Takeda, closed its doors in recent months without a big public disclosure, but multiple employees flashed signals on a networking site.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver disease, today announced the formation of its clinical and scientific advisory boards comprising leading clinical experts in liver disease and hepatocyte transplantation, and world-class scientists pioneering cell and gene technologies.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver failure, today announced that new data from its novel hepatocyte cell therapy platform and universal hepatocyte program will be highlighted in three presentations at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which will be held on May 16-19, 2022, in Washington, D.C. Ambys aims to unlock the full potential of hepatocyte replacement therapy for patients with acute and chronic liver failure and genetic liver diseases.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver failure, today announced the expansion of its leadership team with the appointments of Samira Shaikhly as Chief Human Resources Officer and John McKeon as Vice President of Finance. These executive appointments strengthen Ambys’s leadership team as the company prepares for its next growth phase and advances its lead hepatocyte replacement cell therapy program, AMI-918, toward the clinic.